Hu Lu Dao Shi

Researchers are collecting data on 10,000 patients aged 12 years and older with primary headache disorders and medication-overuse headache in the China HeadAche DIsorders RegiStry (CHAIRS). The study examines biomarkers, brain imaging features, cognitive abilities, genetic characteristics, social and demographic details, medical history, treatments used, and outcomes related to headache disorders, with planned long-term follow-up. Participants include groups with episodic migraine, chronic migraine, medication-overuse headache, new daily persistent headache, and other primary headache types. Some participants receive behavioral follow-up, while others using medications like Yangxue Qingnao Granules or biological treatments such as eptinezumab or erenumab are observed during a 12-week period where treatment decisions and dosing are made by their physicians as part of routine care. Throughout the study, participants undergo assessments including headache frequency, brain MRI changes, cognitive tests like the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Exam (MMSE), genetic analysis, and evaluations of disability, anxiety, and depression over long-term periods up to 10 years. Short-term outcomes such as pain relief two hours after medication are also measured. Follow-up visits may continue annually after the initial 24 months, with data collected during routine clinical visits.